These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24853893)

  • 21. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.
    Klein T; Fujii M; Sandel J; Shibazaki Y; Wakamatsu K; Mark M; Yoneyama H
    Med Mol Morphol; 2014 Sep; 47(3):137-49. PubMed ID: 24048504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.
    Koibuchi N; Hasegawa Y; Katayama T; Toyama K; Uekawa K; Sueta D; Kusaka H; Ma M; Nakagawa T; Lin B; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2014 Nov; 13():157. PubMed ID: 25471116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
    Ishiguro N; Shimizu H; Kishimoto W; Ebner T; Schaefer O
    Drug Metab Dispos; 2013 Jan; 41(1):149-58. PubMed ID: 23073734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
    Steven S; Hausding M; Kröller-Schön S; Mader M; Mikhed Y; Stamm P; Zinßius E; Pfeffer A; Welschof P; Agdauletova S; Sudowe S; Li H; Oelze M; Schulz E; Klein T; Münzel T; Daiber A
    Basic Res Cardiol; 2015 Mar; 110(2):6. PubMed ID: 25600227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition.
    Shi S; Kanasaki K; Koya D
    Biochem Biophys Res Commun; 2016 Feb; 471(1):184-90. PubMed ID: 26826382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
    Sharkovska Y; Reichetzeder C; Alter M; Tsuprykov O; Bachmann S; Secher T; Klein T; Hocher B
    J Hypertens; 2014 Nov; 32(11):2211-23; discussion 2223. PubMed ID: 25215436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
    Xie H; Zeng L; Zeng S; Lu X; Zhao X; Zhang G; Tu Z; Xu H; Yang L; Zhang X; Wang S; Hu W
    Eur J Med Chem; 2013 Oct; 68():312-20. PubMed ID: 23994324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
    Gallwitz B
    Expert Opin Investig Drugs; 2011 Jun; 20(6):723-32. PubMed ID: 21500969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
    Jermendy G
    Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
    Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
    Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linagliptin as add-on therapy for type 2 diabetes - an overview.
    Brown DX; Choudhury M; Evans M
    Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension.
    Chaykovska L; Alter ML; von Websky K; Hohmann M; Tsuprykov O; Reichetzeder C; Kutil B; Kraft R; Klein T; Hocher B
    J Hypertens; 2013 Nov; 31(11):2290-8; discussion 2299. PubMed ID: 24077249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, Synthesis, and Biological Evaluation of Novel Quinazoline Clubbed Thiazoline Derivatives.
    Ali Z; Akhtar MJ; Siddiqui AA; Khan AA; Haider MR; Yar MS
    Arch Pharm (Weinheim); 2017 Feb; 350(2):. PubMed ID: 28093794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.